通过抑制Keap1-Nrf2蛋白-蛋白相互作用激活Nrf2
Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
作者信息
Lee Sumi, Hu Longqin
机构信息
Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, United States.
Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, United States.
出版信息
Med Chem Res. 2020 May;29(5):846-867. doi: 10.1007/s00044-020-02539-y. Epub 2020 Apr 10.
Abstract
Activation of the transcription factor Nrf2 via the Keap1-Nrf2-ARE signaling system regulates the transcription and subsequent expression of cellular cytoprotective proteins and plays a crucial role in preventing pathological conditions exacerbated by the overproduction of oxidative stress. In addition to electrophilic modulators, direct non-covalent inhibitors that interrupt the Keap1-Nrf2 protein-protein interaction (PPI) leading to Nrf2 activation have attracted a great deal of attention as potential preventive and therapeutic agents for oxidative stress-related diseases. Structural studies of Keap1-binding ligands, development of biochemical and cellular assays, and new structure-based design approaches have facilitated the discovery of small molecule PPI inhibitors. This perspective reviews the Keap1-Nrf2-ARE system, its physiological functions, and the recent progress in the discovery and the potential applications of direct inhibitors of Keap1-Nrf2 PPI.
摘要
通过Keap1-Nrf2-ARE信号系统激活转录因子Nrf2可调节细胞保护性蛋白的转录及后续表达，并在预防因氧化应激过度产生而加剧的病理状况中发挥关键作用。除亲电调节剂外，作为氧化应激相关疾病的潜在预防和治疗药物，能够中断Keap1-Nrf2蛋白-蛋白相互作用（PPI）从而导致Nrf2激活的直接非共价抑制剂也引起了广泛关注。Keap1结合配体的结构研究、生化和细胞检测方法的开发以及基于新结构的设计方法促进了小分子PPI抑制剂的发现。本文综述了Keap1-Nrf2-ARE系统、其生理功能以及Keap1-Nrf2 PPI直接抑制剂发现方面的最新进展及其潜在应用。
相似文献
1
Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
Med Chem Res. 2020 May;29(5):846-867. doi: 10.1007/s00044-020-02539-y. Epub 2020 Apr 10.
2
Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
Acta Pharm Sin B. 2015 Jul;5(4):285-99. doi: 10.1016/j.apsb.2015.05.008. Epub 2015 Jul 2.
3
Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.
Curr Med Chem. 2014;21(16):1861-70. doi: 10.2174/0929867321666140217104648.
4
CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Redox Biol. 2019 Sep;26:101266. doi: 10.1016/j.redox.2019.101266. Epub 2019 Jul 2.
5
Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.
Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):259-270. doi: 10.1111/bcpt.13222. Epub 2019 Apr 15.
6
Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Eur J Med Chem. 2020 Dec 1;207:112734. doi: 10.1016/j.ejmech.2020.112734. Epub 2020 Aug 22.
7
Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Bioorg Med Chem Lett. 2017 Nov 15;27(22):5006-5009. doi: 10.1016/j.bmcl.2017.10.008. Epub 2017 Oct 6.
8
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Arch Biochem Biophys. 2017 Oct 1;631:31-41. doi: 10.1016/j.abb.2017.08.003. Epub 2017 Aug 8.
9
Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
J Med Chem. 2018 Sep 27;61(18):8088-8103. doi: 10.1021/acs.jmedchem.8b00358. Epub 2018 May 29.
10
Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
J Med Chem. 2016 Dec 22;59(24):10837-10858. doi: 10.1021/acs.jmedchem.6b00586. Epub 2016 Oct 12.
引用本文的文献
1
Targeting Nrf2 in acute myeloid leukemia: an updated review on its role in chemoresistance and emerging therapeutic strategies.
Med Oncol. 2025 Sep 1;42(10):460. doi: 10.1007/s12032-025-03012-9.
2
Retinal Gatekeepers: Molecular Mechanism and Therapeutic Role of Cysteine and Selenocysteine.
Biomolecules. 2025 Aug 21;15(8):1203. doi: 10.3390/biom15081203.
3
The role of Nrf2 signaling pathway in diabetic cardiomyopathy: from pathogenesis to traditional Chinese medicine interventions.
Front Cardiovasc Med. 2025 Jul 14;12:1492499. doi: 10.3389/fcvm.2025.1492499. eCollection 2025.
4
Synergistic Antioxidant Effects of C3G-Enriched L. cv. RD83 Extract and α-Tocopherol Against HO-Induced Oxidative Stress in SH-SY5Y Cells.
Int J Mol Sci. 2025 Jul 5;26(13):6490. doi: 10.3390/ijms26136490.
5
CB5712809, a novel Keap1 inhibitor upregulates SQSTM1/p62 mediated Nrf2 activation to induce cell death in colon cancer cells.
Discov Oncol. 2025 Jun 1;16(1):981. doi: 10.1007/s12672-025-02787-7.
6
Fam163a knockdown and mitochondrial stress in the arcuate nucleus of hypothalamus reduce AgRP neuron activity and differentially regulate mitochondrial dynamics in mice.
Acta Physiol (Oxf). 2025 Apr;241(4):e70020. doi: 10.1111/apha.70020.
7
A novel KEAP1 inhibitor, tiliroside, activates NRF2 to protect against acetaminophen-induced oxidative stress and acute liver injury.
Hepatol Commun. 2025 Feb 26;9(3). doi: 10.1097/HC9.0000000000000658. eCollection 2025 Mar 1.
8
One-Pot Synthesis of 2-Substituted Indoles and 7-Azaindoles Sequential Alkynylation and Cyclization of 2-Iodo--mesylarylamines and Alkynes in the Presence of CuO.
Asian J Org Chem. 2025 Jan;14(1). doi: 10.1002/ajoc.202400421. Epub 2024 Nov 19.
9
Flavonoids from as neuroprotective agents attenuate cerebral ischemia/reperfusion injury and via activating Nrf2.
Redox Rep. 2025 Dec;30(1):2440204. doi: 10.1080/13510002.2024.2440204. Epub 2024 Dec 19.
10
Modular Nanotransporters Deliver Anti-Keap1 Monobody into Mouse Hepatocytes, Thereby Inhibiting Production of Reactive Oxygen Species.
Pharmaceutics. 2024 Oct 21;16(10):1345. doi: 10.3390/pharmaceutics16101345.
本文引用的文献
1
Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
Bioorg Med Chem. 2020 Mar 15;28(6):115343. doi: 10.1016/j.bmc.2020.115343. Epub 2020 Jan 31.
2
Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.
J Med Chem. 2020 Jun 25;63(12):6547-6560. doi: 10.1021/acs.jmedchem.9b01074. Epub 2019 Nov 14.
3
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
J Med Chem. 2019 Sep 12;62(17):8028-8052. doi: 10.1021/acs.jmedchem.9b00723. Epub 2019 Aug 27.
4
Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development.
Oxid Med Cell Longev. 2019 Jul 14;2019:9372182. doi: 10.1155/2019/9372182. eCollection 2019.
5
Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity.
J Med Chem. 2019 Jul 25;62(14):6796-6813. doi: 10.1021/acs.jmedchem.9b00818. Epub 2019 Jul 17.
6
CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Redox Biol. 2019 Sep;26:101266. doi: 10.1016/j.redox.2019.101266. Epub 2019 Jul 2.
7
Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.
J Med Chem. 2019 May 9;62(9):4683-4702. doi: 10.1021/acs.jmedchem.9b00279. Epub 2019 Apr 25.
8
Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
J Med Chem. 2018 Sep 13;61(17):8029-8047. doi: 10.1021/acs.jmedchem.8b01133. Epub 2018 Aug 31.
9
Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
J Med Chem. 2018 Sep 27;61(18):8088-8103. doi: 10.1021/acs.jmedchem.8b00358. Epub 2018 May 29.
10
Identification of a novel small-molecule Keap1-Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):833-841. doi: 10.1080/14756366.2018.1461856.
Zotero 插件